Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 3,030

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Peptide therapeutics: current status and future directions

Open access
Fosgerau, Keld, Hoffmann, Torsten·2015·Drug Discovery Today
DOI 10.1016/j.drudis.2014.10.003
Open this paper in CoChat — free account

Abstract

Peptides are recognized for being highly selective and efficacious and, at the same time, relatively safe and well tolerated. Consequently, there is an increased interest in peptides in pharmaceutical research and development (R&D), and approximately 140 peptide therapeutics are currently being evaluated in clinical trials. Given that the low-hanging fruits in the form of obvious peptide targets have already been picked, it has now become necessary to explore new routes beyond traditional peptide design. Examples of such approaches are multifunctional and cell penetrating peptides, as well as peptide drug conjugates. Here, we discuss the current status, strengths, and weaknesses of peptides as medicines and the emerging new opportunities in peptide drug design and development.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.drudis.2014.10.003

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Research works printed but not linked: 25

  1. Padhi, 2014, Antimicrobial peptides and proteins in mycobacterial therapy: current status and future prospects, Tuberculosis, 94, 363, 10.1016/j.tube.2014.03.011 · DOI
  2. Buchwald, 2014, Effects on GLP-1, PYY, and leptin by direct stimulation of terminal ileum and cecum in humans: implications for ileal transposition, Surg. Obes. Relat. Dis., 10.1016/j.soard.2014.01.032 · DOI
  3. Giordano, 2014, Neuroactive peptides as putative mediators of antiepileptic ketogenic diets, Front. Neurol., 5, 63, 10.3389/fneur.2014.00063 · DOI
  4. Robinson, 2014, Diversity of conotoxin gene superfamilies in the venomous snail, Conus victoriae, PLOS ONE, 9, e87648, 10.1371/journal.pone.0087648 · DOI
  5. Sheridan, 2012, Proof of concept for next-generation nanoparticle drugs in humans, Nat. Biotechnol., 30, 471, 10.1038/nbt0612-471 · DOI
  6. Steidler, 2009, Actobiotics as a novel method for cytokine delivery, Ann. N. Y. Acad. Sci., 1182, 135, 10.1111/j.1749-6632.2009.05067.x · DOI
  7. Schulte, 2005, Peptides in body fluids and tissues as markers of disease, Expert Rev. Mol. Diagn., 5, 145, 10.1586/14737159.5.2.145 · DOI
  8. Manning, 2010, Stability of protein pharmaceuticals: an update, Pharm. Res., 27, 544, 10.1007/s11095-009-0045-6 · DOI · Paper page
  9. Hamley, 2007, Peptide fibrillization, Angew. Chem. Int. Ed. Engl., 46, 8128, 10.1002/anie.200700861 · DOI · Paper page
  10. Riber, 2013, A novel glucagon analogue, ZP-GA-1, displays increased chemical and physical stability in liquid formulation, Diabetes, 62, A99
  11. Timmerman, 2009, Functional reconstruction of structurally complex epitopes using CLIPSTM technology, Open Vaccine J., 2, 56, 10.2174/1875035400902010056 · DOI
  12. Houston, 1996, Lactam bridge stabilization of alpha-helices: the role of hydrophobicity in controlling dimeric versus monomeric alpha-helices, Biochemistry, 35, 10041, 10.1021/bi952757m · doi:10.1021/bi952757m
  13. Sim, 2012, Directional assembly of alpha-helical peptides induced by cyclization, J. Am. Chem. Soc., 134, 20270, 10.1021/ja3098756 · DOI
  14. Knudsen, 2010, Liraglutide: the therapeutic promise from animal models, Int. J. Clin. Pract. Suppl., 4, 10.1111/j.1742-1241.2010.02499.x · DOI
  15. Bao, 2013, Novel fusion of GLP-1 with a domain antibody to serum albumin prolongs protection against myocardial ischemia/reperfusion injury in the rat, Cardiovasc. Diabetol., 12, 148, 10.1186/1475-2840-12-148 · DOI
  16. Delgado, 1992, The uses and properties of PEG-linked proteins, Crit. Rev. Ther. Drug Carr. Syst., 9, 249
  17. Henry, 2014, Continuous subcutaneous delivery of exenatide via ITCA 650 leads to sustained glycemic control and weight loss for 48 weeks in metformin-treated subjects with type 2 diabetes, J. Diabetes Complicat., 28, 393, 10.1016/j.jdiacomp.2013.12.009 · DOI
  18. Hattori, 2009, The human intestinal microbiome: a new frontier of human biology, DNA Res., 16, 1, 10.1093/dnares/dsn033 · DOI · Paper page
  19. Pocai, 2009, Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice, Diabetes, 58, 2258, 10.2337/db09-0278 · DOI · Paper page
  20. Fosgerau, 2011, The new glucagon-GLP-1 dual agonist ZP2929 in combination with long-acting insulin improves glycemic control without causing weight loss in db/db mice, Diabetes, 60, A408
  21. Fosgerau, 2013, The novel GLP-1-gastrin dual agonist, ZP3022, increases beta-cell mass and prevents diabetes in db/db mice, Diabetes Obes. Metab., 15, 62, 10.1111/j.1463-1326.2012.01676.x · DOI
  22. Just, 2014, The novel GLP-1-GLP-2 dual agonist ZP-GG-72 increases intestinal growth and improves insulin sensitivity in DIO mice, Diabetes, 63, A1
  23. Pocai, 2012, Unraveling oxyntomodulin, GLP1's enigmatic brother, J. Endocrinol., 215, 335, 10.1530/JOE-12-0368 · DOI
  24. Zhou, 2014, Functional selectivity of GPCR signaling in animals, Curr. Opin. Cell Biol., 27, 102, 10.1016/j.ceb.2013.11.010 · DOI
  25. Okarvi, 2008, Peptide-based radiopharmaceuticals and cytotoxic conjugates: potential tools against cancer, Cancer Treat. Rev., 34, 13, 10.1016/j.ctrv.2007.07.017 · DOI

Cited by

See all 3,030

Metadata

Authors
Fosgerau, K., & Hoffmann, T.
Venue
Drug Discovery Today
Publisher
Elsevier BV
Published
2015-01
Volume
20
Issue
1
Pages
122-128
ISSN
1359-6446 (ISSN-L)
DOI
10.1016/j.drudis.2014.10.003
OpenAlex
W1992450378
Cited by
3,030
References
3
FWCI
55.00
Type
journal article
Language
en
Open access
hybrid
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Peptide therapeutics: current status and future directions. https://app.cochat.ai/papers/10.1016/j.drudis.2014.10.003
The paper
Fosgerau, K., & Hoffmann, T. (2015). Peptide therapeutics: current status and future directions. Drug Discovery Today. https://doi.org/10.1016/j.drudis.2014.10.003

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.